(Q35620685)

9 August 2017

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score (English)

1 reference

9 August 2017

S Sahebjam

1

1 reference

9 August 2017

R Aloyz

2

1 reference

9 August 2017

D Pilavdzic

3

1 reference

9 August 2017

M-L Brisson

4

1 reference

9 August 2017

C Ferrario

5

1 reference

9 August 2017

N Bouganim

6

1 reference

9 August 2017

V Cohen

7

1 reference

9 August 2017

W H Miller

8

1 reference

9 August 2017

L C Panasci

9

1 reference

9 August 2017

language of work or name

English

0 references

publication date

4 October 2011

1 reference

British Journal of Cancer

9 August 2017

1 reference

9 August 2017

105

1 reference

9 August 2017

1342-1345

1 reference

9 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.402

9 August 2017

0 references

cites work

Ki67 in breast cancer: prognostic and predictive potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

Proliferation marker Ki-67 in early breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

Predicting aggressive outcome in T1N0M0 breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241562

Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies.

12 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.402

Histopathologic variables predict Oncotype DX recurrence score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.402

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.402

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.402

A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.402

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.402

Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.402

Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21970880

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21970880

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.402

1 reference

9 August 2017

1 reference

9 August 2017

1 reference